CSF1 and triple-negative breast carcinoma: The evidence collected thus far suggests that the CSF1 enhancer is specific to triple-negative breast cancer, may be conferring growth advantages to tumor cells, and a reduction in CSF1 leads to changes in the expression of several other genes.